KR102312088B1 - 항인플루엔자 바이러스 피리미딘 유도체 - Google Patents
항인플루엔자 바이러스 피리미딘 유도체 Download PDFInfo
- Publication number
- KR102312088B1 KR102312088B1 KR1020197009275A KR20197009275A KR102312088B1 KR 102312088 B1 KR102312088 B1 KR 102312088B1 KR 1020197009275 A KR1020197009275 A KR 1020197009275A KR 20197009275 A KR20197009275 A KR 20197009275A KR 102312088 B1 KR102312088 B1 KR 102312088B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- mmol
- acceptable salt
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C1=C(C=C(C)C=*)C(C)=*C1 Chemical compound C*C1=C(C=C(C)C=*)C(C)=*C1 0.000 description 5
- MWHRXKUSFTUVNI-AMDVSUOASA-N C#[O]C([C@H]1C(CC2)CCC2C1)=O Chemical compound C#[O]C([C@H]1C(CC2)CCC2C1)=O MWHRXKUSFTUVNI-AMDVSUOASA-N 0.000 description 1
- CDLCNZQETXKSCI-SGLHQCCPSA-N CCOC([C@@H](C1CCC2CC1)C2Nc1c(C)c(Cl)c(C)c(C2(CC2)F)c1F)=O Chemical compound CCOC([C@@H](C1CCC2CC1)C2Nc1c(C)c(Cl)c(C)c(C2(CC2)F)c1F)=O CDLCNZQETXKSCI-SGLHQCCPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610804101.3 | 2016-09-05 | ||
| CN201610804101 | 2016-09-05 | ||
| CN201611238759 | 2016-12-28 | ||
| CN201611238759.9 | 2016-12-28 | ||
| PCT/CN2017/100461 WO2018041263A1 (zh) | 2016-09-05 | 2017-09-05 | 抗流感病毒嘧啶衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190056380A KR20190056380A (ko) | 2019-05-24 |
| KR102312088B1 true KR102312088B1 (ko) | 2021-10-14 |
Family
ID=61300177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197009275A Active KR102312088B1 (ko) | 2016-09-05 | 2017-09-05 | 항인플루엔자 바이러스 피리미딘 유도체 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11136319B2 (enExample) |
| EP (1) | EP3502112B1 (enExample) |
| JP (1) | JP6838773B2 (enExample) |
| KR (1) | KR102312088B1 (enExample) |
| CN (3) | CN110627784B (enExample) |
| AU (1) | AU2017320088B2 (enExample) |
| CA (1) | CA3035680C (enExample) |
| DK (1) | DK3502112T3 (enExample) |
| IL (1) | IL265166B (enExample) |
| MX (1) | MX394277B (enExample) |
| RU (1) | RU2727772C1 (enExample) |
| SG (1) | SG11201901894TA (enExample) |
| WO (1) | WO2018041263A1 (enExample) |
| ZA (1) | ZA201901886B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018033082A1 (en) | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2018041091A1 (en) | 2016-08-30 | 2018-03-08 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| US11136319B2 (en) * | 2016-09-05 | 2021-10-05 | Guangdong Raynovent Biotech Co., Ltd. | Anti-influenza virus pyrimidine derivative |
| US10987354B2 (en) | 2016-12-15 | 2021-04-27 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| WO2018127096A1 (en) * | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US11535613B2 (en) | 2018-03-05 | 2022-12-27 | Guangdong Raynovent Biotech Co., Ltd. | Crystal form and salt form of pyridoimidazole compound and preparation method therefor |
| CN110590768B (zh) * | 2018-06-13 | 2021-02-26 | 银杏树药业(苏州)有限公司 | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 |
| CN114127068B (zh) * | 2019-07-22 | 2024-05-28 | 广东众生睿创生物科技有限公司 | 嘧啶衍生物的优势盐型及其晶型 |
| CN114502150B (zh) * | 2019-09-10 | 2023-03-24 | 广东众生睿创生物科技有限公司 | 一种用于治疗病毒性感冒的药物组合物及其制剂 |
| CN111454166B (zh) * | 2019-12-30 | 2021-02-26 | 广东莱佛士制药技术有限公司 | 制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
| CN113116899B (zh) * | 2020-03-06 | 2022-12-20 | 广东众生睿创生物科技有限公司 | 一种用于治疗流感的药物组合物及含有该药物组合物的制剂 |
| CN116323593B (zh) * | 2020-10-29 | 2025-06-03 | 广东众生睿创生物科技有限公司 | 一种嘧啶衍生物的晶型及其制备方法 |
| CN114569562B (zh) * | 2020-12-01 | 2025-07-29 | 南通诺泰生物医药技术有限公司 | 一种抗流感病毒的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101903354B1 (ko) * | 2009-06-17 | 2018-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| EP2651940A1 (en) | 2010-12-16 | 2013-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| US20130102600A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| KR102488479B1 (ko) * | 2014-08-08 | 2023-01-12 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 |
| CN109748915B (zh) * | 2015-12-09 | 2021-03-26 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| WO2017133657A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2018033082A1 (en) | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| US11136319B2 (en) * | 2016-09-05 | 2021-10-05 | Guangdong Raynovent Biotech Co., Ltd. | Anti-influenza virus pyrimidine derivative |
| US11535613B2 (en) * | 2018-03-05 | 2022-12-27 | Guangdong Raynovent Biotech Co., Ltd. | Crystal form and salt form of pyridoimidazole compound and preparation method therefor |
| CN114127068B (zh) * | 2019-07-22 | 2024-05-28 | 广东众生睿创生物科技有限公司 | 嘧啶衍生物的优势盐型及其晶型 |
-
2017
- 2017-09-05 US US16/330,353 patent/US11136319B2/en active Active
- 2017-09-05 CN CN201910800685.0A patent/CN110627784B/zh active Active
- 2017-09-05 RU RU2019109246A patent/RU2727772C1/ru active
- 2017-09-05 DK DK17845565.5T patent/DK3502112T3/da active
- 2017-09-05 JP JP2019512638A patent/JP6838773B2/ja active Active
- 2017-09-05 SG SG11201901894TA patent/SG11201901894TA/en unknown
- 2017-09-05 KR KR1020197009275A patent/KR102312088B1/ko active Active
- 2017-09-05 AU AU2017320088A patent/AU2017320088B2/en active Active
- 2017-09-05 WO PCT/CN2017/100461 patent/WO2018041263A1/zh not_active Ceased
- 2017-09-05 CN CN201780054195.XA patent/CN109790159B/zh active Active
- 2017-09-05 CN CN201910800902.6A patent/CN110623958B/zh active Active
- 2017-09-05 MX MX2019002541A patent/MX394277B/es unknown
- 2017-09-05 EP EP17845565.5A patent/EP3502112B1/en active Active
- 2017-09-05 CA CA3035680A patent/CA3035680C/en active Active
-
2019
- 2019-03-04 IL IL265166A patent/IL265166B/en unknown
- 2019-03-27 ZA ZA2019/01886A patent/ZA201901886B/en unknown
-
2021
- 2021-08-24 US US17/410,801 patent/US11725009B2/en active Active
-
2023
- 2023-06-19 US US18/337,329 patent/US12319692B2/en active Active
-
2025
- 2025-04-28 US US19/191,976 patent/US20250250275A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102312088B1 (ko) | 항인플루엔자 바이러스 피리미딘 유도체 | |
| TWI504604B (zh) | 雜環化合物及其用途 | |
| JP2019529386A5 (enExample) | ||
| AU2018209573A1 (en) | ASK1 inhibitor and preparation method and use thereof | |
| EP3555070A1 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| JP7237010B2 (ja) | Ｈｄａｃ６選択的阻害剤およびその製造方法と使用 | |
| KR102254660B1 (ko) | Ａ2ａ수용체 억제제로서의 축합 고리 유도체 | |
| CN107573333B (zh) | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 | |
| JP7050054B2 (ja) | Ｐｄｅ４阻害剤としての縮合環系化合物 | |
| KR102547709B1 (ko) | 아제티딘 유도체 | |
| CN111635373B (zh) | 多环磺酰胺类RORγ调节剂 | |
| HK40003826A (en) | Anti-influenza virus pyrimidine derivatives | |
| HK40003826B (en) | Anti-influenza virus pyrimidine derivatives | |
| JP2019524810A (ja) | 抗ｈｃｍｖウイルス化合物 | |
| BR112019004420B1 (pt) | Composição farmacêutica | |
| WO2024094875A1 (en) | Chromen-4-one compounds with anticancer properties | |
| OA19666A (en) | Amine-substituted heterocyclic compounds as Ehmt2 inhibitors and methods of use thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 5 |